[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100422000":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":28,"locations":33,"responsibleParty":48,"collaborators":10,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":10,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":10,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Universitaire Ziekenhuizen KU Leuven","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Subjects with earlier PCR-proven COVID-19 and\u002For serum anti-SARS-CoV-2 antibodies",null,"Patients that require a medically indicated pulmonary resection.",[13],"Diagnostic Test: Lung biopsy",{"label":15,"type":10,"description":11,"interventionNames":16},"Subjects WITHOUT earlier PCR-proven COVID-19 and\u002For serum anti-SARS-CoV-2 antibodies",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DIAGNOSTIC_TEST","Lung biopsy","Biopsy of residuary material from a medically indicated pulmonary resection",[15,9],[24],{"name":25,"affiliation":26,"role":27},"Laurens J Ceulemans, MD, PhD","UZ Leuven","PRINCIPAL_INVESTIGATOR",[29],{"name":25,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","+ 32 16 34 34 25","laurens.ceulemans@uzleuven.be",[34],{"facility":26,"status":35,"city":36,"state":10,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Leuven","3000","Belgium","BE",{"type":41,"coordinates":42},"Point",[43,44],4.70093,50.87959,{"lat":44,"lon":43},[47],{"name":25,"role":30,"phone":31,"phoneExt":10,"email":32},{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100422000","residual-sars-cov-2-presence-in-the-respiratory-tract-and-lung-parenchyma-after-sars-cov-2-infection-or-covid-19-100422000",false,"NCT04775134","Residual SARS-CoV-2 Presence in the Respiratory Tract and Lung Parenchyma (After SARS-CoV-2 Infection or COVID-19)","Residual SARS-CoV-2 Presence in the Respiratory Tract and Lung Parenchyma","REASSURE","Inclusion Criteria:\n\n* Patient requires medically indicated pulmonary resection\n* Informed consent\n\nExclusion Criteria:\n\n* Active SARS-CoV-2 infection\u002FCOVID-19\n* No informed consent","ALL","18 Years",{"count":61,"type":62},75,"ESTIMATED","OBSERVATIONAL","The aim of this study is to confirm or rule out the residual presence and viability of SARS- CoV-2 in the respiratory tract and lung parenchyma of patients previously infected with SARS-CoV-2.\n\nPresence and viability of SARS-CoV-2 in lung tissue will be assessed with reverse transcriptase-polymerase chain reaction (PCR) and viral culture. The histological location of residual SARS-CoV-2 will be determined with fluorescence immunohistochemistry and single molecule fluorescence in situ hybridization, targeting viral proteins and RNA respectively.",[66],"Covid19","2024-07-01",{"date":69,"type":70},"2024-07-03","ACTUAL",{"date":72,"type":70},"2021-01-31",{"date":74,"type":62},"2025-12-31",{"name":5,"class":6},1]